ClinicalTrials.gg
RecruitingNCT07023627MAESTRA 1Updated Sep 15, 2026

A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

A Phase 2 interventional study of INCB123667 in Ovarian Cancer, sponsored by Incyte Corporation. Recruiting at 74 sites in 8 countries. Open to female participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-09-15.

Sponsored by Incyte Corporation · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Nov 2025; still recruiting 1 year later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
160
Allocation
Non-randomized
Ages
18 Years to 99 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies in Ovarian Neoplasms by Incyte Corporation — 3 open to participants now, 3 under way, 2 of them phase 3. Ovarian Neoplasms · Incyte Corporation.

Planned enrollment
5th of 17
160 · median 87
Started
2025
with 1 other
Phase 2
2 of 17
1 open now
Registered
15th of 17
by date

Among the 17 studies in Ovarian Neoplasms by Incyte Corporation, this one is the 5th largest by planned enrollment, is one of 2 that started in 2025, is one of 2 in phase 2, and was the 15th registered.

Ovarian Neoplasms

3,387 studies on the registry are indexed under Ovarian Neoplasms; 791 are open to participants now.

Browse Ovarian Neoplasms studies →

Open to participants now

3 of the 17 studies in Ovarian Neoplasms by Incyte Corporation are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 602 Ovarian Neoplasms studies recruiting now, 439 (73%) set no upper age limit and 107 (18%) stop at 75 or younger; 39 take children under 18; 45 take healthy volunteers.

This study: 18 Years to 99 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Ovarian Neoplasms by Incyte Corporation, or all of them as a file.
02

Study summary

This study will evaluate the safety and efficacy of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer (PROC) With Cyclin E1 Overexpression.

03

Conditions studied

  • Ovarian Cancer

Browse trials for

Keywords

  • INCB123667
04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Histological diagnosis of a high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer.
  • Have platinum-resistant disease:

    • Participants who have only had 1 line of platinum-based therapy must have received at least 4 cycles of a platinum-containing regimen.
    • Participants who have received 2 to 4 lines of platinum-based therapy must have progressed on or within 6 months after the last dose of platinum.
  • Willingness to undergo a pretreatment . Note: Tissue from a fresh pretreatment biopsy is preferred, however an archival sample is acceptable as long as the sample is no older than 5 years.
  • Received at least 1 and no more than 4 following the initial diagnosis, after which single-agent therapy is considered an appropriate next therapeutic option.
  • Must have received bevacizumab unless there was a for its use.
  • If the tumor tests positive for FRα, participants must have received mirvetuximab soravtansine unless there is an exception for its use on medical grounds.

Exclusion criteria

Exclusion Criteria:

  • Have endometrioid, clear cell, mucinous, or sarcomatous histology, mixed tumors containing any of these histologies, or low-grade/borderline ovarian cancer.
  • Have primary platinum- disease: either did not respond (CR or PR) to platinum-containing therapy or progressed on or within 3 months after the last dose of the first line platinum-containing therapy.
  • The tumor tests positive for FRα but the participant has not received mirvetuximab soravtansine for any reason other than medical .
  • or uncontrolled cardiac disease within 6 months before the first dose of study drug.
  • Known active and/or carcinomatous meningitis.
  • Known additional that is progressing or requires active treatment.

Other protocol-defined Inclusion/Exclusion Criteria may apply.

Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
160 participants (estimated)

Study arms

  • Experimental
    Cohort 1

    INCB123667 will be administered at the protocol defined dose based on their tumor cyclin E1 expression levels as defined in the protocol.

    Drug: INCB123667

  • Experimental
    Cohort 2

    INCB123667 will be administered at the protocol defined dose based on their tumor cyclin E1 expression levels as defined in the protocol.

    Drug: INCB123667

  • Experimental
    Cohort 3

    INCB123667 will be administered at the protocol defined dose based on their tumor cyclin E1 expression levels as defined in the protocol.

    Drug: INCB123667

Interventions

  • Administered orally twice daily (BID).

06

What researchers measure

Primary outcomes

  1. Objective Response by IRC

    Defined as having a confirmed best overall response of complete response (CR) or partial response (PR), as determined by independent review committee (IRC) assessment per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.

    Time frame: Up to 2 years

Secondary outcomes

  1. Duration of Response (DOR) by IRC

    Defined as the time from the earliest date of CR or PR contributing to a subsequently confirmed CR or PR until the earliest date of disease progression, as determined by IRC assessment per RECIST v1.1, or death due to any cause, whichever occurs first.

    Time frame: Up to 2 years

  2. Progression-Free Survival (PFS) by IRC

    Defined as the time from the date of first dose of study drug until the earliest date of disease progression as determined by IRC assessment per RECIST v1.1, or death due to any cause, whichever occurs first.

    Time frame: Up to 2 years

  3. Overall Survival (OS)

    Defined as the time from the date of first dose of study drug until death due to any cause.

    Time frame: Up to 2 years

  4. Objective Response by Investigator

    Defined as having a confirmed best overall response of CR or PR, as determined by investigator assessment per RECIST v1.1.

    Time frame: Up to 2 years

  5. DOR by investigator

    Defined as the time from the earliest date of CR or PR contributing to a subsequently confirmed CR or PR until the earliest date of disease progression, as determined by investigator assessment per RECIST v1.1, or death due to any cause, whichever occurs first.

    Time frame: Up to 2 years

  6. PFS by Investigator

    Defined as the time from the date of first dose of study drug until the earliest date of disease progression, as determined by investigator assessment per RECIST v1.1, or death due to any cause, whichever occurs first.

    Time frame: Up to 2 years

  7. Treatment Emergent Adverse Events (TEAE'S)

    Adverse events reported for the first time or worsening of a pre-existing event after first dose of study drug until 30 days after the last dose of study drug or the start of new anticancer therapy, whichever occurs first.

    Time frame: Up to 2 years and 30 days

  8. TEAEs leading to dose interruptions, dose reductions or discontinuation of study treatment

    TEAEs leading to dose interruptions, dose reductions or discontinuation of study treatment.

    Time frame: Up to 2 years and 30 days

07

Study locations

74 of 74 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Incyte shares data with qualified external researchers after a research proposal is submitted. These requests are reviewed and approved by a review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. The trial data availability is according to the criteria and process described on https://www.incyte.com/our-company/compliance-and-transparency

Supporting information: Study protocol, Statistical analysis plan

Time frame: Data will be shared after the primary publication or 2 years after the study has ended for market authorized products and indications.

Access criteria: Data from eligible studies will be shared with qualified researchers according to the criteria and process described in the Data Sharing section of the www.incyteclinicaltrials.com website. For approved requests, the researchers will be granted access to anonymized data under the terms of a data sharing agreement.

Data sharing details ↗ · www.incyte.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for Apr 2027, 17 months after the start.

Of 116 industry-sponsored phase 2 interventional studies under Ovarian Neoplasms, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 51. This study's planned 17 months is below that.

Counting every sponsor, half of 344 studies reached it within 47 months; a quarter within 33 and three quarters within 72.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 9, 2025
First posted
Jun 17, 2025
StartActual
Nov 12, 2025
Primary completionEst.
Apr 27, 2027
CompletionEst.
Oct 24, 2027
Last update
Sep 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07023627
Lead sponsor
Incyte Corporation
Collaborators
ENGOT Foundation, GOG Foundation
Responsible party
Sponsor
First posted
Jun 17, 2025
Start date
Nov 12, 2025
Primary completion
Apr 27, 2027 (estimated)
Completion
Oct 24, 2027 (estimated)
Last update
Sep 15, 2026

Study contacts

Incyte Corporation Call Center (US)
Contact
medinfo@incyte.com
1.855.463.3463
Incyte Corporation Call Center (ex-US)
Contact
eumedinfo@incyte.com
+800 00027423
Incyte Medical Monitor
study director · Incyte Corporation

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: CDK2 Inhibitor INCB123667

Start the discussion